Table 1. Baseline patient demographics and clinicopathologic features of papillary thyroid carcinoma in two data-set.
| Variables Mean age (years) |
This study (n = 512) 47.0 ± 13.3 |
TCGA 46.8 ± 15.5 |
|---|---|---|
| Age (years) | n = 364 | |
| < 45 | 213 (41.6%) | 168 (46.2%) |
| ≥ 45 | 299 (58.4%) | 196 (53.8%) |
| Sex | n = 364 | |
| Female | 405 (79.1%) | 271 (74.5%) |
| Male | 107 (20.9%) | 93 (25.5%) |
| Multifocality | NA | |
| Single | 290 (56.6%) | |
| Multiple | 222 (43.4%) | |
| Histologic variants | n = 364 | |
| Classic | 451 (88.1%) | 249 (68.4%) |
| Follicular variant | 16 (3.1%) | 81 (22.3%) |
| Tall cell variant | 21 (4.1%) | 28 (7.7%) |
| Others | 24 (4.7%) | 6 (1.6%) |
| Tumor size (cm) | 1.6 ± 0.7 | NA |
| pT stage | n = 362 | |
| pT1-2 | 138 (27.0%) | 231 (63.8%) |
| pT3-4 | 374 (73.0%) | 131 (36.2%) |
| Extrathyroidal extension | n = 354 | |
| Absent | 137 (26.8%) | 250 (70.6%) |
| Present | 375 (73.2%) | 104 (29.4%) |
| pN stage | n = 364 | |
| pN0 | 160 (31.3%) | 172 (47.3%) |
| pN1 | 323 (63.1%) | 153 (42.0%) |
| pNx | 29 (5.7%) | 39 (10.7%) |
| Lateral LN metastasis | n = 325 | |
| Absent | 408 (79.7%) | 277 (85.2%) |
| Present | 104 (20.3%) | 48 (14.8%) |
| Distant metastasis | n = 363 | |
| Absent | 505 (98.6%) | 357 (98.3%) |
| Present | 7 (1.4%) | 6 (1.7%) |
| AJCC stage | n = 362 | |
| I | 248 (48.4%) | 209 (57.7%) |
| II | 93 (18.2%) | 41 (11.3%) |
| III | 121 (23.6%) | 77 (21.3%) |
| IV | 50 (9.8%) | 35 (9.7%) |
| BRAF V600E mutation | n = 428 | n = 375 |
| Absent | 75 (17.5%) | 147 (39.2%) |
| Present | 353 (82.5%) | 228 (60.8%) |
| Dyscohesive cells | NA | |
| 0% | 163 (31.8%) | |
| 1%-10% | 159 (31.1%) | |
| 11%-20% | 113 (22.1%) | |
| ≥ 20% | 77 (15.0%) | |
| Psammoma bodies | NA | |
| 0 | 298 (58.2%) | |
| 1–3 | 135 (26.4%) | |
| ≥ 4 | 79 (15.4%) | |
| Persistent/Recurrent disease | NA | |
| Absent | 476 (93.0%) | |
| Present | 36 (7.0%) |
TCGA, The Cancer Genome Atlas; NA, not available.